Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016824623> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W3016824623 endingPage "1" @default.
- W3016824623 startingPage "1" @default.
- W3016824623 abstract "An oxycodone vaccine (OXY-sKLH) is being developed to treat opioid use disorder. OXY-sKLH has been demonstrated to be effective at blocking clinically relevant doses of oxycodone and reducing its reinforcing efficacy. To further assess the potential of OXY-sKLH for clinical use, critical in vivo properties of the vaccine were studied. Sprague Dawley rats were vaccinated with OXY-sKLH or control vaccine (sKLH alone) in alum adjuvant. Exposure of vaccinated rats to oxycodone weekly confirmed the expectation that oxycodone alone does not boost oxycodone-specific antibody titers in vaccinated rats. Re-vaccination with OXY-sKLH was necessary to maintain titers. In a separate experiment, antibody titers of vaccinated rats showed a titer of 1.6 × 105 after the final vaccine dose which declined to 0.54 × 105 at 3 months. Vaccine specificity for oxycodone was assessed in vivo. Vaccination protected against oxycodone-induced, but not methadone-induced, antinociception. Administration of naloxone to vaccinated rats that had received methadone partially restored nociception and fully reversed respiratory depression. Vaccination of rats with OXY-sKLH did not alter the pharmacokinetics or antinociception of subsequently administered fentanyl. These in vivo data confirm the previously reported in vitro specificity of this vaccine for oxycodone. Finally, vaccination with OXY-sKLH extended oxycodone’s half-life from 0.75 hr in control rats to 24 hr. Taken together, these results indicate that antibody titers generated by OXY-sKLH are long lasting, and will not interfere with clinically useful non-targeted opioids, and will decline even in the face of continued oxycodone exposure unless boosted by re-vaccination. The prolonged oxycodone half-life in vaccinated rats suggests the potential for antibody saturation if oxycodone exposure continues and is substantial and persistent. Support or Funding Information This work was supported by the National Institutes of Health National Institute on Drug Abuse [Grant U01DA038876] (to M.P. and P.R.P.)" @default.
- W3016824623 created "2020-04-24" @default.
- W3016824623 creator A5004598118 @default.
- W3016824623 creator A5004660654 @default.
- W3016824623 creator A5011990703 @default.
- W3016824623 creator A5018846327 @default.
- W3016824623 creator A5019893864 @default.
- W3016824623 creator A5024624450 @default.
- W3016824623 creator A5047686095 @default.
- W3016824623 creator A5071953967 @default.
- W3016824623 date "2020-04-01" @default.
- W3016824623 modified "2023-09-26" @default.
- W3016824623 title "Functional in vivo characteristics of antibodies generated by an oxycodone vaccine" @default.
- W3016824623 doi "https://doi.org/10.1096/fasebj.2020.34.s1.03354" @default.
- W3016824623 hasPublicationYear "2020" @default.
- W3016824623 type Work @default.
- W3016824623 sameAs 3016824623 @default.
- W3016824623 citedByCount "0" @default.
- W3016824623 crossrefType "journal-article" @default.
- W3016824623 hasAuthorship W3016824623A5004598118 @default.
- W3016824623 hasAuthorship W3016824623A5004660654 @default.
- W3016824623 hasAuthorship W3016824623A5011990703 @default.
- W3016824623 hasAuthorship W3016824623A5018846327 @default.
- W3016824623 hasAuthorship W3016824623A5019893864 @default.
- W3016824623 hasAuthorship W3016824623A5024624450 @default.
- W3016824623 hasAuthorship W3016824623A5047686095 @default.
- W3016824623 hasAuthorship W3016824623A5071953967 @default.
- W3016824623 hasBestOaLocation W30168246231 @default.
- W3016824623 hasConcept C112705442 @default.
- W3016824623 hasConcept C126322002 @default.
- W3016824623 hasConcept C150903083 @default.
- W3016824623 hasConcept C159654299 @default.
- W3016824623 hasConcept C170493617 @default.
- W3016824623 hasConcept C203014093 @default.
- W3016824623 hasConcept C207001950 @default.
- W3016824623 hasConcept C22070199 @default.
- W3016824623 hasConcept C22889606 @default.
- W3016824623 hasConcept C2776029756 @default.
- W3016824623 hasConcept C2777863537 @default.
- W3016824623 hasConcept C2781063702 @default.
- W3016824623 hasConcept C2781072394 @default.
- W3016824623 hasConcept C32611913 @default.
- W3016824623 hasConcept C42219234 @default.
- W3016824623 hasConcept C71924100 @default.
- W3016824623 hasConcept C86803240 @default.
- W3016824623 hasConcept C98274493 @default.
- W3016824623 hasConceptScore W3016824623C112705442 @default.
- W3016824623 hasConceptScore W3016824623C126322002 @default.
- W3016824623 hasConceptScore W3016824623C150903083 @default.
- W3016824623 hasConceptScore W3016824623C159654299 @default.
- W3016824623 hasConceptScore W3016824623C170493617 @default.
- W3016824623 hasConceptScore W3016824623C203014093 @default.
- W3016824623 hasConceptScore W3016824623C207001950 @default.
- W3016824623 hasConceptScore W3016824623C22070199 @default.
- W3016824623 hasConceptScore W3016824623C22889606 @default.
- W3016824623 hasConceptScore W3016824623C2776029756 @default.
- W3016824623 hasConceptScore W3016824623C2777863537 @default.
- W3016824623 hasConceptScore W3016824623C2781063702 @default.
- W3016824623 hasConceptScore W3016824623C2781072394 @default.
- W3016824623 hasConceptScore W3016824623C32611913 @default.
- W3016824623 hasConceptScore W3016824623C42219234 @default.
- W3016824623 hasConceptScore W3016824623C71924100 @default.
- W3016824623 hasConceptScore W3016824623C86803240 @default.
- W3016824623 hasConceptScore W3016824623C98274493 @default.
- W3016824623 hasIssue "S1" @default.
- W3016824623 hasLocation W30168246231 @default.
- W3016824623 hasOpenAccess W3016824623 @default.
- W3016824623 hasPrimaryLocation W30168246231 @default.
- W3016824623 hasRelatedWork W1539989077 @default.
- W3016824623 hasRelatedWork W1934038313 @default.
- W3016824623 hasRelatedWork W2019316759 @default.
- W3016824623 hasRelatedWork W2043515767 @default.
- W3016824623 hasRelatedWork W2357466682 @default.
- W3016824623 hasRelatedWork W2411735003 @default.
- W3016824623 hasRelatedWork W2418494490 @default.
- W3016824623 hasRelatedWork W2468132621 @default.
- W3016824623 hasRelatedWork W4210513646 @default.
- W3016824623 hasRelatedWork W4307264905 @default.
- W3016824623 hasVolume "34" @default.
- W3016824623 isParatext "false" @default.
- W3016824623 isRetracted "false" @default.
- W3016824623 magId "3016824623" @default.
- W3016824623 workType "article" @default.